Food and Drug Administration director-general Dr. Samuel Zacate vowed to remove red tape and introduce innovations within the agency in support of the President’s desire for more accessible and lower-priced medicines by ensuring fair competition in the pharmaceutical sector.
Zacate, appointed by President Ferdinand Marcos Jr. to head the FDA in August, said the agency would undergo a much-needed overhaul as it gears toward becoming a world-class regulatory body.
“The long culture of the FDA being on the safe side and being inside the box is long gone because I’m here now,” Zacate said Tuesday at the general membership meeting of the Philippine Chamber of Pharmaceutical Industry Inc.
Zacate, a diplomate of the Philippine Society of Venereology and a fellow of the International College of Surgeons, is a public health advocate with years of expertise in medicine and medical consultancy.
“I cannot let the President fail. So now, I am telling you, I am a man of innovation. I don’t want to be inside the box. I am not keen on the idea that we cannot do something [to a problem] because everything, especially with science, is possible,” he said.
The FDA, a regulatory agency mandated to ensure the safety, efficacy and quality of health products in the country, plays a crucial role, especially since global health emergencies—Covid-19 and monkeypox –still pose risks in the healthcare system.
Zacate also vowed to ensure the accessibility of medicines and make it less burden on Filipinos.
“As a physician, I did not realize that there would come a time when it would be hard for us to access medicines. During the height of the pandemic, we could not even get simple paracetamol or decongestant, which are usually readily available in pharmacies. So, I told the President that this is a problem,” he said.
He vowed to support the President’s call for a robust local pharmaceutical manufacturing sector to ensure that the country’s supply of much-needed essential medicines.
“I always make sure to have plans but I know my limitations, that’s why I am asking you to bring up to me the problems you are encountering in the industry and we will meet halfway.”
Zacate assured industry stakeholders that under his leadership, the FDA would ensure that the registration process would be more efficient. In doing so, the FDA chief said both manufacturers and consumers would benefit.
“With regard to the FDA, they have stringent requirements and internal processes, but now I have the power to streamline the internal processes, mostly on payments, assessments and rigid [regulatory] conditions. I will do it,” Zacate said.
“For example, in terms of the importation process, we will try to make it more efficient. There is an ongoing mechanism for registration. I am trying to improvise the Information Technology System of the Center for Drug Regulation and Research. There will come a time when importation will be streamlined,” he said.
